{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-23-209064","form_type":"8-K","ticker":"SPRO","cik":"0001701108","company_name":"Spero Therapeutics, Inc.","filed_at":"2023-08-10T23:59:59+00:00","discovered_at":"2026-05-14T18:03:34.903690+00:00","generated_at":"2026-06-11T18:17:23.835884+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Spero reports Q2 loss $11.9M; FDA SPA for tebipenem HBr P3 trial","bullets":["Net loss $11.9M ($0.23/sh) vs $28.7M ($0.87) in Q2 2022; revenue $2.7M.","FDA SPA agreement on design of Phase 3 PIVOT-PO trial for tebipenem HBr; first patient expected Q4 2023.","Sath Shukla appointed President and CEO effective Aug 1; succeeds Ankit Mahadevia (now Chairman).","Cash $77.7M + $30M GSK milestone; cash runway into H2 2025.","SPR720 Phase 2 trial enrolling, topline data H2 2024; SPR206 IND planned Q4 2023."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-23-209064","json":"https://secwatch.observer/filing/0001193125-23-209064.json","markdown":"https://secwatch.observer/filing/0001193125-23-209064.md","text":"https://secwatch.observer/filing/0001193125-23-209064.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1701108/000119312523209064/0001193125-23-209064-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1701108/000119312523209064/d494367d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-11T18:17:23.835884+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"b79ff50c0adf4d765fd2e24e6e2d49da0792f3d7","claim":"Spero Therapeutics, Inc. reported second quarter ended June 30, 2023 results: revenue $2.7 million, net income net loss of $11.9 million, EPS $0.23 per basic and diluted share.","evidence_excerpt":"Spero reported a net loss for the second quarter ended June 30, 2023 of $11.9 million or $0.23 per basic and diluted share of common stock, compared to a net loss of $28.7 million or $0.87 per basic and diluted share of common stock reported for the same period in 2022. Total revenues for the second quarter of 2023 were $2.7 million","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1701108/000119312523209064/0001193125-23-209064-index.htm","confidence":0.98,"family_label":"Earnings Releases","details":[{"label":"Period","value":"second quarter ended June 30, 2023"},{"label":"Revenue","value":"$2.7 million"},{"label":"Net income","value":"net loss of $11.9 million"},{"label":"EPS","value":"$0.23 per basic and diluted share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}